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Introduction
Blastic plasmacytoid dendritic cell 
neoplasm (BPDCN) is a rare, highly 
aggressive hematopoietic malignancy.1 It 
manifests as cutaneous and bone marrow 
involvement and leukemic spread. It 
represents 0.7% of primary cutaneous 
lymphomas. Recently, it was established as 
a distinct entity.2 We present a rare case of 
BPDCN with good response to chemo-
therapy and review the clinicopathologic 
features of this disease. 
 
Case Report 
A 67-year-old man was admitted to the 
hospital because of a 6-month history of 
fatigue, weight loss, and cough. On physical 
examination, he manifested hepatospleno-
megaly with multiple palpable bilateral 
axillary and inguinal lymph nodes. Cell 
count and basic metabolic profile were 
within normal ranges. Computed tomo-
graphy (CT) scan of the chest, abdomen, and 
pelvis demonstrated multiple axillary, 
mediastinal, intra- and retro-peritoneal 
centimetric and infracentimetric lymph 
nodes, splenomegaly (21 cm), and 
hepatomegaly (21 cm).  
Histopathological examination of the 
right axillary lymph node biopsy specimen 
revealed atypical interfollicular and 
medullary infiltrate composed of mono-
tonous monomorphous population of small 
to medium cells with round and oval nuclei, 
finely dispersed chromatin, small nucleoli, 
and scant cytoplasm admixed with scattered 
transformed lymphocytes and histiocytes. 
Immunohistochemical staining, performed 
on formalin fixed, paraffin-embedded tissue, 
showed a strong expression of CD5 in the 
tumor cells. CD10 was slightly positive. The 
CD3 showed many small CD3 positive T-
cells predominantly surrounding the intact 
follicles, and scattered within the inter-
follicular and medullary infiltrates. The 
CD34 was negative in the infiltrates and 
positive in the vasculature. TdT showed 
rare, scattered weakly positive cells within 
the infiltrates. The CD7, CD123 and TCL-1 
were positive on numerous cells within the 
infiltrate. Other stains (CD20, CD38, CD57, 
PAX-5) were negative. Ki-67 stained 
approximately 30% of the tumor nuclei.  
Bone marrow studies showed an 
interstitial infiltrate composed of small to 
intermediate sized atypical immature cells 
with round and oval nuclei, dispersed 
chromatin, and indistinct nucleoli. Immuno-
histochemical studies were performed. CD4 
and CD56 showed no tissue staining likely 
secondary to tissue process/technical issues. 
CD5 showed scattered small CD5 positive 
T-cells throughout the bone marrow 
interstitium. CD123 and TLC-1 stains were 
similar in appearance and highlighted a 
predominantly interstitial infiltrate that 
represented approximately 10-20% of the 
total bone marrow cellularity.  
The patient was diagnosed with BPDCN 
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based on his clinical and histopathological 
findings. He received four cycles of 
cyclophosphamide, hydroxydaunorubicin, 
vincristine, and prednisone (CHOP).  
Repeated CT, four months later, showed 
a decrease in mediastinal adenopathies and 
spleen size. Also, a bone marrow study 
showed less than 3% of expressing plasma 
cells. The patient was scheduled for a total 
of four additional cycles of CHOP with 
follow-up imaging. 
 
Discussion 
BPDCN was described in 2008 and 
classified as an acute myeloid leukemia and 
related precursor neoplasms.2 In 2001, the 
World Health Organization (WHO) 
classified it as “blastic natural killer cell 
lymphoma”.3 In 2005, it was termed 
CD4+/CD56+ hematodermic neoplasm in the 
WHO-European Organization for Research 
and Treatment of Cancer classification.4 
BPDCN affects primarily the elderly and 
has an aggressive clinical course with a poor 
prognosis.5-7 Ninety percent of cases pre-
sented with asymptomatic solitary/multi-
focal cutaneous reddish-brown nodules or 
bruise-like lesions.5,6 Bone marrow was 
involved in most cases, however, any organ, 
can be affected. Extramedullary leukemic 
infiltration may precede acute myeloid 
leukemia. The disease follows a short course 
and fulminant leukemia is the common 
terminal stage. 
Histopathologically, the neoplastic cells 
are characterized by monotonous non-
epidermotropic infiltration of uniform 
medium-sized cells with round nuclei and 
finely dispersed chromatin and absent or 
indistinct nucleoli, resembling lymphoblast 
or myeloblasts.8,9 The cytoplasm is scant, 
difficult to visualize, and never exhibits 
granulation. The typical monomorphous, 
blastic neoplastic cell morphology is evident 
in only 44.4% of cases.  
Diagnosis is made by the immuno-
phenotypic features of the malignant cells. 
However, cytogenetic analysis is not helpful 
since no recurrent specific chromosomal 
aberrations were recognized.10,11 Flow 
cytometry is preferred over immuno-
histochemical analysis as it allows for the 
examination of more markers and their 
intensity determination. BPDCN is defined 
by the expression of CD4, CD56, and 
CD123 in the absence of T-cell, B-cell, or 
myeloid markers.5-11 The Ki-67 labeling 
index of BPDCN reportedly ranges from 
20% to 90%.8 However, the neoplastic cells 
of BPDCN show a greater variability of 
morphologic and immunophenotypic fea-
tures.8,9 Ascani et al.12 and Aragrakos et al.13 
reported a CD4-negative variant of BPDCN. 
Cases of CD56-negative and CD123 nega-
tive BPDCN also have been reported.8  
The prognosis of BPDCN is poor, with a 
median survival period of 14 months, and 
with two- and five-year overall survival 
rates of 33% and 6%, respectively.14 There 
is no consensus on the optimal treatment for 
BPDCN. The therapeutic approaches 
described in the literature are very different 
and not standardized. Initially, most patients 
show a good response to treatment, but 
relapse quickly.15 Long-term remissions 
rarely have been reported in younger 
patients who received acute leukemia-type 
induction therapy and allogeneic stem cell 
transplantation.9,16 
 
Conclusion  
BPDCN should be considered in the 
differential diagnosis of hematopoietic 
tumors, especially due to the diversity of cell 
morphology. Accurate diagnosis requires 
careful histologic examination and 
appropriate immunohistochemical and flow 
cytometry panels, including CD4, CD56, 
TCL1, and CD123. This variant should be 
recognized to make an early diagnosis. Once 
diagnosed, patients can be managed 
properly. 
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